



Identification of 5 novel germline APC mutations and characterization of clinical phenotypes in Japanese patients with classical and attenuated familial adenomatous polyposis.

メタデータ	言語: English					
	出版者:					
	公開日: 2013-08-27					
	キーワード (Ja):					
	キーワード (En):					
	作成者: Hong, Tao, Shinmura, Kazuya, Yamada,					
	Hidetaka, Maekawa, Masato, Osawa, Satoshi,					
	Takayanagi, Yasuhiro, Okamoto, Kazuya, Terai,					
	Tomohiro, Mori, Hiroki, Nakamura, Toshio, Sugimura					
	Haruhiko					
	メールアドレス:					
	所属:					
URL	http://hdl.handle.net/10271/2366					

SHORT REPORT



Open Access

Identification of 5 novel germline APC mutations and characterization of clinical phenotypes in Japanese patients with classical and attenuated familial adenomatous polyposis

Hong Tao¹, Kazuya Shinmura¹, Hidetaka Yamada¹, Masato Maekawa², Satoshi Osawa³, Yasuhiro Takayanagi³, Kazuya Okamoto⁴, Tomohiro Terai³, Hiroki Mori¹, Toshio Nakamura⁵, Haruhiko Sugimura^{1*}

Abstract

Background: Familial adenomatous polyposis (FAP) is an autosomal dominant hereditary disease characterized by multiple colorectal adenomatous polyps and frequent extracolonic manifestations. An attenuated form of FAP (AFAP) is diagnosed based on a milder colorectal phenotype, and the colorectal phenotype of (A)FAP has been linked to germline *APC* mutations. The relationships between the spectrum of mutations and extracolonic manifestations are quite well known, but they need to be further defined.

Findings: Nine germline *APC* mutations, but no large deletions, were identified in the *APC* locus of 8 (A)FAP patients, and 5 of the mutations, c.446A > T (p.Asp149Val), c.448A > T (p.Lys150X), c.454_457insAGAA (p. Glu152ArgfsX17), c.497insA (p.Thr166AsnfsX2), and c.1958G > C (p.Arg653Ser), were novel mutations. In one patient the p.Asp149Val mutation and p.Lys150X mutation were detected in the same *APC* allele. The c.1958G > C mutation was located in the last nucleotide of exon 14, and RT-PCR analysis revealed that the mutation resulted in abnormal splicing. The above findings meant that a nonsense mutation, a frameshift mutation, or an exonic mutation leading to abnormal splicing was found in every patient. The following phenotypes, especially extracolonic manifestations, were observed in our (A)FAP patients: (1) multiple gastroduodenal adenomas and early-onset gastric carcinoma in AFAP patients with an exon 4 mutation; (2) a desmoid tumor in two FAP patients with a germline *APC* mutation outside the region between codons 1403 and 1578, which was previously reported to be associated with the development of desmoid tumors in FAP patients; (3) multiple myeloma in an AFAP patient with an exon 4 mutation.

Conclusions: Nine germline *APC* mutations, 5 of them were novel, were identified in 8 Japanese (A)FAP patients, and some associations between germline *APC* mutations and extracolonic manifestations were demonstrated. These findings should contribute to establishing relationships between germline *APC* mutations and the extracolonic manifestations of (A)FAP patients in the future.

Background

Familial adenomatous polyposis (FAP) is an autosomal dominant familial cancer syndrome characterized by the early onset of large numbers of adenomatous polyps throughout the entire colon and a nearly 100% lifetime risk of colorectal cancer (CRC) if the colon is not removed [1]. A small proportion of familial colorectal polyposis cases were recently found to be associated with biallelic germline mutations of the *MutYH* gene [2]. However most FAP cases are caused by germline mutations of the tumor suppressor gene *adenomatous polyposis coli (APC)*, which encodes a 2843-amino-acid protein that contains a variety of functional domains involved in cell cycle control, differentiation, transcription, migration, and apoptosis [3]. More than 1000 pathogenetic mutations have been detected throughout



© 2010 Sugimura et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

^{*} Correspondence: hsugimur@hama-med.ac.jp

¹First Department of Pathology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi Ward, Hamamatsu, Shizuoka 431-3192, Japan Full list of author information is available at the end of the article

the APC gene, and the lifetime penetrance of the disease is close to 100% [3-5]. Some FAP cases have been classified as 'attenuated FAP (AFAP)' because of their attenuated phenotypes. Although there is still no consensus as to the precise definition of AFAP, some papers have summarized the characteristics of AFAP as follows: development of far fewer colorectal adenomatous polyps in AFAP patients than in classical FAP and the onset of adenomatous polyps and colorectal cancer 10~15 years later in AFAP patients than in classical FAP [6-8]. The germline APC mutations in AFAP patients have been found to occur at the 5' end and 3' end and in a specific region of exon 9 of the APC gene, in contrast to the germline APC mutations in classical FAP patients, which are found in other locations [3,8-10]. Thus, the analysis of the sites and spectrum of germline APC mutations in patients with multiple colorectal polyps is very important to the proper management of (A)FAP.

A number of extracolonic phenotypic manifestations are associated with FAP: upper gastrointestinal tract polyps and cancer, desmoid tumors, thyroid cancer, hepatoblastoma, congenital hypertrophy of the retinal pigment epithelium (CHRPE), and other extracolonic malignancies [1,3]. One of them, CHRPE, only occurs in patients with germline APC mutations between codons 457 and 1444, and desmoid tumors develop only in patients having mutations between codons 1403 and 1578 [1,3]. Although the correlations between the germline APC genotypes and FAP phenotypes are well known, they need to be further defined. In this study we investigated the genes of 8 Japanese (A)FAP patients for germline APC mutations, and we identified 9 germline APC mutations, including 5 novel ones. We also discuss possible relationships between the germline APC mutations and extracolonic manifestations in our (A)FAP patients.

Methods

Subjects

Blood samples were obtained from 5 patients with classical FAP and 3 patients with attenuated FAP, all of whom appeared to be unrelated, in the hospital of Hamamatsu University School of Medicine. Written informed consent was obtained from every patient. Lymphocyte genomic DNAs were extracted from the blood samples with a QIAamp DNA Blood Maxi kit (QIA-GEN, Hilden, Germany). This study was approved by the Institutional Review Board of the Hamamatsu University School of Medicine (18-4).

Conventional sequencing analysis of the APC gene

The 1st-15th exons of *APC* and their boundary regions were amplified by polymerase chain reaction (PCR) and directly sequenced with ABI BigDye Terminator Ready

Reaction Mix (Applied Biosystems, Foster City, CA, USA) and an ABI 3100 Genetic Analyzer (Applied Biosystems) [11]. Information regarding the PCR primers is available upon request. Subcloning of the PCR fragments was performed by using a pGEM-T Easy TA Cloning Kit (Promega, Madison, WI) according to the supplier's protocol.

Calculation of splicing efficiency and detection of the exonic splicing enhancer (ESE) sequence

The splicing efficiency of the wild-type allele and the mutant-type allele of the patient with c.1958G > C mutation was predicted by using the Berkeley Drosophila Genome Project (BDGP) splice prediction program [12]. The effect of the exonic mutation on putative ESE sites was predicted by the ESEfinder software program [13]. ESEfinder is a web-based resource that facilitates rapid analysis of exon sequences to identify binding motifs for serine/arginine-rich (SR) proteins.

APC mRNA transcript analysis

RNAs were extracted from blood samples with a PAXgene Blood RNA Kit (QIAGEN) and converted to firststrand cDNAs by using a SuperScript First-Strand Synthesis System for reverse transcription (RT)-PCR (Invitrogen, Carlsbad, CA, USA) according to the supplier's protocol [14]. RT-PCR was performed with a set of primers, i.e., 5'-aaa gac gtt gcg aga agt tg-3' for the sequence of exon 13 and 5'-caa acc tcg ctt tga aga ag-3' for the sequence of exon 15, and the products were separated on 2% agarose gel and stained with ethidium bromide before being examined with an ultraviolet imaging system. The splicing rates were evaluated by comparing the intensities of the two main bands detected in each sample by using ImageJ software (National Institutes of Health, USA) as reported previously [15].

Multiple ligation-dependent probe amplification (MLPA) analysis

A MLPA kit (P043 APC) was purchased from MRC-Holland (Amsterdam, The Netherlands), and reactions were carried out according to the manufacturer's instructions. Probe ratios below 0.7 and above 1.3 are regarded as indicative of a decrease and increase, respectively, of gene dosage.

Results

Identification of 5 novel germline APC mutations

Genomic DNA sequencing of the entire *APC* coding regions and exon-intron boundaries enabled identification of a total of 9 germline *APC* mutations in 8 unrelated Japanese (A)FAP patients (Table 1). Five of the 9 germline *APC* mutations identified in this study, i.e., c.446A > T (p.Asp149Val), c.448A > T (p.Lys150X),

Patient ID	Germline <i>APC</i> mutation ¹ (Exon ²)	Consequence	Reference ³	FAP type (age ⁴)	Number ⁵ of colorectal polyps	Colorectal cancer (age)	Extracolonic manifestation (age ⁴)
1	c.446A > T (4)	p.Asp149Val	This study	AFAP (34)	40-100	Absent (38 ⁶)	Gastric adenocarcinoma (34)
	c.448A > T (4)	p.Lys150X	This study				Multiple gastroduodenal adenomas(34)
2	c.454_457insAGAA (4)	p.Glu152ArgfsX17	This study	AFAP (29)	40-100	Present (51 ⁶)	Gastric hyperplastic polyps (29)
3	c.497insA (4)	p.Thr166AsnfsX2	This study	AFAP (69)	> 100	Present (69 ⁴)	Multiple gastroduodenal adenomas (69) Multiple myeloma (69)
4	c.1958G > C (14)	p.Arg653Ser	This study	FAP (32)	> 300	Present (32 ⁴)	Multiple gastroduodenal adenomas (32)
		Aberrant splicing					Duodenal adenocarcinoma (32)
5	c.1993_1994delTT (15)	p.Leu664llefsX8	[19]	FAP (28)	> 300	NA ⁷	Desmoid tumor (31) Multiple gastroduodenal adenomas (41) Small intestinal adenocarcinoma (41)
6	c.3505_3509delGAGAA (15)	p.Glu1169ThrfsX8	[20]	FAP (19)	> 300	Absent (19 ⁶)	Multiple gastroduodenal polyps (19)
7	c.3747C > A (15)	p.Cys1249X	[21]	FAP (22)	> 1000	Present (22 ⁴)	Multiple gastroduodenal adenomas (22) Desmoid tumor (25)
8	c.3927_3931delAAAGA (15)	p.Glu1309AspfsX4	[21]	FAP (31)	> 1000	Present (31 ⁴)	Multiple gastroduodenal polyps (31) Papillary thyroid cancer (31)

Table 1 Germline APC mutations and clinical phenotypes identified in 8 Japanese (A)FAP patients

¹The reference sequence of the APC gene [GenBank:NM_000038] was used. Nucleotide +1 is the A of the ATG-translation initiation codon.

²The exon that contained the ATG-translation initiation codon was regarded as the first exon.

³When a germline APC mutation had been reported previously, the paper reporting it is cited.

⁴Age at diagnosis is shown.

⁵The number of colorectal polyps refers to the cumulative number.

⁶Age at last observation is shown.

⁷NA: not available.

c.454 457insAGAA (p.Glu152ArgfsX17), c.497insA (p. Thr166AsnfsX2), and c.1958G > C (p.Arg653Ser), had never been reported in any articles according to the information in the Human Gene Mutation Database or in the APC variant databases in the Leiden Open Variation Database (LOVD) [16-18], and none were found in a thorough review of the literature, indicating that they are novel mutations. Sequencing of the subcloned APC fragments revealed that the c.446A > T mutation and c.448A > T mutation detected in Patient 1 were located on the same APC allele (Figure 1a). Since the c.448A >T mutation is a nonsense mutation, the c.448A > T mutation is more likely than the c.446A > T missense mutation to be a disease-causing mutation. The c.454_457insAGAA mutation detected in Patient 2 and the c.497insA mutation detected in Patient 3 are frameshift type mutations and lead to the formation of premature stop codons (Figure 1b, c). The c.1958G > C mutation detected in Patient 4 was associated with an amino acid substitution (p.Arg653Ser) and was located in the last nucleotide of exon 14 (Figure 1d). The remaining 4 *APC* mutations had been reported previously [19-21].

Detection of abnormal splicing caused by the novel APC mutation c.1958G > C

The novel mutation c.1958G > C detected in Patient 4 was localized in the last nucleotide of exon 14, and three germline APC mutations, i.e., c.1956C > T, c.1957A > C, and c.1957A > G very close to c.1958G > C, have previously been reported to induce abnormal splicing of exon 14 [22]. Moreover, a severe reduction in splicing efficiency was predicted for the c.1958G > C mutation by the BDGP splice prediction program, and disruption of the binding site for one of the SR proteins, SC35, by the mutation was predicted by the ESEfinder program for splicing enhancer's motif prediction (Table 2). These predictions prompted us to examine the effect of the c.1958G > C mutation on splicing by mRNA transcript analysis. An RNA sample from the patient with the c.1958G/C genotype and two RNA samples from two control subjects with the c.1958G/G



Table 2 Prediction of the effects of the c.1958G > C mutation on splicing

Allele	Splice prediction ¹	ESE score for SC35 ²
Wild type (G)	0.91	4.595
Mutant type (C)	<0.01	_3

¹Predicted by the Berkeley Drosophila Genome Project (BDGP) splice prediction program.

²Exonic splicing enhancer (ESE) score as predicted by ESEfinder. Its threshold score for SC35 protein is 2.383.

³Below the threshold score.

genotype were prepared and used for RT-PCR analysis with a forward primer for the sequence on exon 13 and a reverse primer for the sequence on exon 15. Two main bands were detected in all samples (Figure 2), and direct sequencing of the two bands revealed that the upper band (band A) represented the wild-type fragment and the lower band (band B) represented the whole exon 14-skipped product (data not shown), findings that are consistent with those reported in a previous paper [22]. Calculation of the splicing rate of the mutant-type transcript by dividing the intensity of band B by the intensity of band A with the ImageJ program showed that the splicing rate in samples with the G/C genotype was higher than in samples with the G/G genotype (1.24) vs 0.23 and 0.31) (Figure 2), suggesting that the c.1958G > C mutation caused abnormal splicing.

Confirmation of the c.454_457insAGAA mutation and the c.3927_3931delAAAGA mutation by MLPA analysis

To better evaluate the state of the genomic DNA of (A) FAP patients, MLPA analysis, which is useful for detecting large deletions and duplications, was also performed on all 8 samples. No increased signals were detected, but decreased signals were detected in two patients. One decreased signal was detected in APC exon 4 of the DNA derived from Patient 2 (Figure 3a). However, no large deletions were detected in mRNA transcripts from Patient 2 by RT-PCR analysis with a forward primer for the sequence of exon 2 and a reverse primer for the sequence of exon 6 (data not shown). Examination of the sequence of the DNA probe for APC exon 4 revealed that the probe for exon 4 overlapped with the c.454_457insAGAA mutation (p.Glu152ArgfsX17) in Patient 2. Thus, it is likely that the overlapping caused the disruption of the MLPA reactions in the DNA. The other decreased signal was detected with the p.1309 mutation-specific probe in Patient 8 (Figure 3b). These results were consistent with the results of the sequencing analysis (p.Glu1309AspfsX4 mutation) in the patient. The results of the MLPA analysis in conjunction with the sequencing analysis indicated that base substitutions or microdeletions, not large deletions or duplications, in the APC gene locus caused the production of truncated APC proteins in our (A)FAP patients.

Characterization of clinical phenotypes of patients with different germline *APC* mutations

The clinical phenotypes of all 8 patients are summarized in Table 1. All 3 patients (Patients 1-3) with a mutation in *APC* exon 4 had been diagnosed with AFAP because of their attenuated colorectal phenotypes. From 40 to 100 colorectal polyps were detected in Patient 1. Patient 2 was found to have a relatively small number of colorectal polyps at 29 years of age, and clinical follow up was performed instead of surgical treatment. At 51 years of age, however, an early-stage CRC and approximately 100 colorectal adenomatous polyps were detected, and total colectomy was performed. A sister of Patient 2 was also diagnosed with AFAP and found to have the same







APC mutation, but none of the 6 unaffected members of this family was found to have the family-specific mutation. Colon fiberscopy was performed for the first time in Patient 3 when he was 69 years old because of rectal bleeding, and more than 100 colorectal adenomatous polyps and multiple advanced-stage CRCs were observed. Total colectomy was performed, but the patient died of liver and lung metastases 7 years later.

By contrast, more than 300 colorectal adenomatous polyps were found in each of the other 5 patients, who were diagnosed with classical FAP. The mother of Patient 4 and the daughter of Patient 5 were found to have their family-specific *APC* mutation, consistent with their FAP phenotype. Among the extracolonic manifestations, gastroduodenal polyps, which are also common in FAP patients, were observed in all of the patients

with classical and attenuated FAP in this study. Most of the polyps in the stomach were histologically diagnosed as fundic gland polyps. However, multiple adenomas were observed in the stomach and duodenum of Patients 1, 3, 4, 5, and 7. Desmoid tumors are common in FAP patients and were observed in Patients 5 and 7. Malignant neoplasms in the form of gastric carcinoma, multiple myeloma, duodenal carcinoma, small intestinal carcinoma, and thyroid carcinoma developed in Patient 1, Patient 3, Patient 4, Patient 5, and Patient 8, respectively. No extracolonic manifestations were detected in the other (A)FAP affected members of any of the families, or such information was unavailable.

Discussion

Sequencing analysis, RT-PCR analysis, and MLPA analysis of the APC genes of 8 Japanese (A)FAP patients from 8 unrelated families revealed a nonsense mutation, a frameshift mutation, or an exonic mutation leading to abnormal splicing, all of which resulted in the production of a truncated APC protein, in every patient. No large deletions or duplications in the APC locus were detected in any of the patients. Five of the 9 germline APC mutations detected in this study had never been reported before, meaning that they are novel mutations. Since two mutations, c.446A > T (p.Asp149Val) and c.448A > T (p.Lys150X), are on the same allele and located close to each other, it is possible that these two mutations are in complete linkage disequilibrium but are not two independent mutations. Consistent with the previous finding that mutations in the 5' and 3' ends and in exon 9 of the APC gene are associated with having the attenuated type of FAP [6-10], the mutations in exon 4 were found in the 3 AFAP patients in this study, and the mutations in exons 14, and 15 were found in the 5 classical FAP patients in this study.

Knowledge of genotype-phenotype correlations in (A) FAP has been accumulating, and it is useful in the clinical management of (A)FAP families, but the relationships between the locations of the APC mutations and extracolonic manifestations are still not fully understood. Furthermore, as the number of patients diagnosed with (A)FAP has increased, a broad range of variable extracolonic manifestations has gradually come to be recognized in (A)FAP patients. Based on the results of APC mutations and extracolonic manifestations observed in our study, we focused our attention on the following three issues. First, fundic gland polyps, not gastric adenoma, have been reported to be the main gastric lesions in AFAP patients [1,8]. Interestingly, multiple adenomas in the stomach, in addition to the commonly detected fundic gland polyps, as well as in the duodenum were observed in 2 of our 3 AFAP patients with germline mutations in APC exon 4, and a gastric adenocarcinoma was also found in one of them at 34 years of age. As far as we know [7,8], this is the first report of such an early-onset gastric cancer in AFAP patients. Gastric adenocarcinomas have been reported in (A)FAP patients [23-26], but the mechanism of involvement of the APC mutation in the gastric carcinogenesis remains largely unknown. There have been reports of gastric adenocarcinomas in (A)FAP patients having arisen from a fundic gland polyp or adenoma, and the reports suggested the existence of an adenomaadenocarcinoma sequence in their carcinogenesis [23-25]. However, there have been other reports claiming to have found no relation between a gastric adenocarcinoma in an AFAP patient and existing fundic gland polyps or adenomas [26]. Analysis of the APC inactivation status in the adenomas and adenocarcinomas detected in our patients may help to better understand the mechanism of the involvement of APC mutations in tumorigenesis. In addition to genetic factors, various environmental factors have been reported to affect the risk of gastric cancer [27-29], environmental factors and genes that modify the development of gastric lesions may be involved in the clinical phenotype. The second issue is that it has previously been reported that there is a close association between the presence of a germline APC mutation between codons 1403 and 1578 in FAP patients and the occurrence of desmoid tumors [1,3], however, both of the FAP patients with a desmoid tumor in our series had a germline APC mutation outside the region, i.e., in codon 664 and codon 1249. Some other recent papers have also reported the occurrence of desmoid tumors in FAP patients with APC mutations outside the region between codons 1403 and 1578 [30,31]. Thus, the results of this study and others together with the findings described in previous reviews [1,3] have suggested that although FAP-associated desmoids predominantly occur in patients carrying APC mutations between codons 1403 and 1578, some of them occur outside the region. The third issue that we focused our attention on is that a multiple myeloma was detected in one of our 3 AFAP patients with a germline exon 4 mutation. This is the first report of complication of AFAP by multiple myeloma. However, evidence of APC involvement, such as a second somatic mutation of APC in multiple myeloma, needs to be found in order to rule out the possibility that the occurrence of the multiple myeloma was a coincidental unrelated event. We think that although the number of cases analyzed was relatively small, the above three findings will contribute to establishing relationships between germline APC abnormalities and clinical phenotypes in (A)FAP patients and to better characterizing the differences between APC-related polyposis and MutYH-associated polyposis in the future. However, since many examples

of deviations from observed *APC* genotype-FAP phenotype correlations and highly variable phenotypic traits have been reported [16,32-34], it has been pointed out that the family history is important in (A)FAP genotypephenotype analyses and the factors other than the *APC* genotype may be involved in producing the (A)FAP phenotype.

Although a nearly 100% risk of CRC has been reported in patients with classical FAP, the lifetime risk of CRC in AFAP patients is unclear. At the time this study was performed CRC had been diagnosed in Patient 2 at 51 years of age and Patient 3 at 69 years of age, but not in Patient 1, who was 38 years old. Lifetime risk of CRC is an important factor in the clinical management and genetic counselling of AFAP patients, especially because it affects the decision as to whether to proceed with prophylactic colectomy. The results of this study should contribute to determining the lifetime risk of CRC in AFAP patients in the future.

The results of the RT-PCR analysis in this study showed that a G to C transversion at c.1958, which corresponds to the last nucleotide of exon 14 of the *APC* gene, causes abnormal splicing. Since APC mRNA transcript analyses in previous studies have demonstrated that exonic single-base substitutions of c.423G > T, c.834G > C, c.1869G > T, c.1918C > G, c.1956C > T, c.1957A > C, and c.1957A > G affect splicing [22,35-37], c.1958G > C is the 8th *APC* exonic mutation that has been demonstrated to result in abnormal splicing. Interestingly, most (6 out of 8) of the exonic mutations associated with abnormal splicing have been located in exon 14, but the reason for this clustering is unclear.

Conclusions

In the present study, 9 germline *APC* mutations, 5 of which were novel, were identified in 8 Japanese (A)FAP patients. The following three findings regarding the relation between the location of the germline *APC* mutations and extracolonic manifestations were also obtained in this study: 1) severe gastric lesions occurred in AFAP patients with an exon 4 mutation, 2) desmoid tumors developed in FAP patients with germline *APC* mutations outside the region between codons 1403 and 1578, 3) a multiple myeloma developed in an AFAP patient with an exon 4 mutation. These findings should contribute to increasing our knowledge of the associations between *APC* genotypes and (A)FAP phenotypes, which are informative for proper clinical management and genetic counselling of (A)FAP patients and their families.

Acknowledgements

This work was supported in part by a Grant-in-Aid from the Ministry of Health, Labour and Welfare for the Comprehensive 10-Year Strategy for Cancer Control (19-19) and the Third Term Comprehensive Control Research

for Cancer, JSPS KAKENHI (22590356), MEXT KAKENHI (18014009), and a Grant-in-Aid from the Smoking Research Foundation.

Author details

¹ First Department of Pathology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi Ward, Hamamatsu, Shizuoka 431-3192, Japan. ²Department of Laboratory Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi Ward, Hamamatsu, Shizuoka 431-3192, Japan. ³First Department of Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi Ward, Hamamatsu, Shizuoka 431-3192, Japan. ⁴Department of Surgery, Fujinomiya City General Hospital, 3-1 Nishikicho, Fujinomiya, Shizuoka 418-0076, Japan. ⁵Second Department of Surgery, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi Ward, Hamamatsu, Shizuoka 431-3192, Japan.

Authors' contributions

HT carried out the mutation detection and molecular genetic analyses, collected up the clinical data, participated in the design of the study, and drafted the manuscript. KS participated in the design of the study and drafted the manuscript. HY extracted the total RNAs from blood samples. MM, SO, YT, KO, TT, HM and TN identified relevant patients for genetic testing and were responsible for clinicopathological data. HS and MM conceived of the study, participated in the design of the study, and drafted the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 22 June 2010 Accepted: 16 November 2010 Published: 16 November 2010

References

- Galiatsatos P, Foulkes WD: Familial adenomatous polyposis. Am J Gastroenterol 2006, 101:385-398.
- Al-Tassan N, Chmiel NH, Maynard J, Fleming N, Livingston AL, Williams GT, Hodges AK, Davies DR, David SS, Sampson JR, Cheadle JP: Inherited variants of MYH associated with somatic G:CXT:A mutations in colorectal tumors. *Nature Genet* 2002, 30:227-232.
- Fearnhead NS, Britton MP, Bodmer WF: The ABC of APC. Hum Mol Genet 2001, 10:721-733.
- Groden J, Thliveris A, Samowitz W, Carlson M, Gelbert L, Albertsen H, Joslyn G, Stevens J, Spirio L, Robertson M, Sargeant L, Krapcho K, Wolff E, Burt R, Hughes JP, Warrington J, McPherson J, Wasmuth J, Le Paslier D, Abderrahim H, Cohen D, Leppert M, White R: Identification and characterization of the familial adenomatous polyposis coli gene. *Cell* 1991, 9:589-600.
- Nagase H, Miyoshi Y, Horii A, Aoki T, Petersen GM, Vogelstein B, Maher E, Ogawa M, Maruyama M, Utsunomiya J, Baba S, Nakamura Y: Screening for germ-line mutations in familial adenomatous polyposis patients: 61 new patients and a summary of 150 unrelated patients. *Hum Mutat* 1992, 1:467-473.
- Samowitz WS, Thliveris A, Spirio LN, White R: Alternatively spliced adenomatous polyposis coli (APC) gene transcripts that delete exons mutated in attenuated APC. *Cancer Res* 1995, 55:3732-3734.
- Soravia C, Berk T, Madlensky L, Mitri A, Cheng H, Gallinger S, Cohen Z, Bapat B: Genotype-phenotype correlations in attenuated adenomatous polyposis coli. Am J Hum Genet 1998, 62:1290-1301.
- Knudsen AL, Bisgaard ML, Bülow S: Attenuated familial adenomatous polyposis (AFAP). A review of the literature. Fam Cancer 2003, 2:43-55.
- Heppner Goss K, Trzepacz C, Tuohy TM, Groden J: Attenuated APC alleles produce functional protein from internal translation initiation. Proc Natl Acad Sci USA 2002, 99:8161-8166.
- Neklason DW, Solomon CH, Dalton AL, Kuwada SK, Burt RW: Intron 4 mutation in APC gene results in splice defect and attenuated FAP phenotype. *Fam Cancer* 2004, 3:35-40.
- Tao H, Shinmura K, Suzuki M, Kono S, Mibu R, Tanaka M, Kakeji Y, Maehara Y, Okamura T, Ikejiri K, Futami K, Yasunami Y, Maekawa T, Takenaka K, Ichimiya H, Imaizumi N, Sugimura H: Association between genetic polymorphisms of the base excision repair gene MUTYH and increased colorectal cancer risk in a Japanese population. *Cancer Sci* 2008, **99**:355-360.

- 12. The Berkeley Drosophila Genome Project (BDGP). [http://www.fruitfly.org/seq_tools/splice.html].
- Cartegni L, Wang J, Zhu Z, Zhang MQ, Krainer AR: ESEfinder: a web resource to identify exonic splicing enhancers. *Nucleic Acid Res* 2003, 31:3568-3571.
- Shinmura K, Kageyama S, Igarashi H, Kamo T, Mochizuki T, Suzuki K, Tanahashi M, Niwa H, Ogawa H, Sugimura H: EML4-ALK fusion transcripts in immunohistochemically ALK-positive non-small cell lung carcinomas. *Exp Ther Med* 2010, 1:271-275.
- Yamada H, Sugimura H, Tsuneyoshi T: Suppressive effect of epigallocatechin gallate (EGCg) on DNA methylation in mice: Detection by methylation sensitive restriction endonuclease digestion and PCR. J Food Agr Environ 2005, 3:73-76.
- The Human Gene Mutation Database. [http://www.hgmd.cf.ac.uk/ac/index. php].
- 17. **The** *APC* **variant database in Leiden Open Variation Database.** [http:// chromium.liacs.nl/LOVD2/colon_cancer/home.php?select_db=APC].
- The APC variant database in Zhejiang University Center for Genetic and Genomic Medicine. [http://www.genomed.org/lovd/hnpcc/home.php? select_db=APC].
- Enomoto M, Konishi M, Iwama T, Utsunomiya J, Sugihara KI, Miyaki M: The relationship between frequencies of extracolonic manifestations and the position of APC germline mutation in patients with familial adenomatous polyposis. Jpn J Clin Oncol 2000, 30:82-88.
- Friedl W, Caspari R, Sengteller M, Uhlhaas S, Lamberti C, Jungck M, Kadmon M, Wolf M, Fahnenstich J, Gebert J, Möslein G, Mangold E, Propping P: Can APC mutation analysis contribute to therapeutic decisions in familial adenomatous polyposis? Experience from 680 FAP families. *Gut* 2001, 48:515-521.
- Aretz S, Uhlhaas S, Sun Y, Pagenstecher C, Mangold E, Caspari R, Möslein G, Schulmann K, Propping P, Friedl W: Familial adenomatous polyposis: aberrant splicing due to missense or silent mutations in the APC gene. *Hum Mutat* 2004, 24:370-380.
- Miyoshi Y, Ando H, Nagase H, Nishisho I, Horii A, Miki Y, Mori T, Utsunomiya J, Baba S, Petersen G, Hamilton SR, Kinzler KW, Vogelstein B, Nakamura Y: Germ-line mutations of the APC gene in 53 familial adenomatous polyposis patients. Proc Natl Acad Sci USA 1992, 89:4452-4456.
- 23. Jagelman DG, DeCosse JJ, Bussey HJ: Upper gastrointestinal cancer in familial adenomatous polyposis. *Lancet* 1988, 1:1149-1151.
- Church JM, McGannon E, Hull-Boiner S, Sivak MV, Van Stolk R, Jagelman DG, Fazio VW, Oakley JR, Lavery IC, Milsom JW: Gastroduodenal polyps in patients with familial adenomatous polyposis. *Dis Colon Rectum* 1992, 35:1170-1173.
- Zwick A, Munir M, Ryan CK, Gian J, Burt RW, Leppert M, Spirio L, Chey WY: Gastric adenocarcinoma and dysplasia in fundic gland polyps of a patient with attenuated adenomatous polyposis coli. *Gastroenterology* 1997, 113:659-663.
- Takeda A, Bau S, Hirooka E, Takahashi K, Ohara Y, Nakayama H, Shinozuka N, Koyama I: Gastric carcinogenesis after long-term observation of clinical course without any treatment in a patient with attenuated familial adenomatous polyposis. J Clin Pathol 2006, 59:890-891.
- Tao H, Shinmura K, Hanaoka T, Natsukawa S, Shaura K, Koizumi Y, Kasuga Y, Ozawa T, Tsujinaka T, Li Z, Yamaguchi S, Yokota J, Sugimura H, Tsugane S: A novel splice-site variant of the base excision repair gene MYH is associated with production of an aberrant mRNA transcript encoding a truncated MYH protein not localized in the nucleus. *Carcinogenesis* 2004, 25:1859-1866.
- Yamada H, Shinmura K, Okudela K, Goto M, Suzuki M, Kuriki K, Tsuneyoshi T, Sugimura H: Identification and characterization of a novel germ line p53 mutation in familial gastric cancer in the Japanese population. *Carcinogenesis* 2007, 28:2013-2018.
- Milne AN, Carneiro F, O'Morain C, Offerhaus GJ: Nature meets nurture: molecular genetics of gastric cancer. Hum Genet 2009, 126:615-628.
- Latchford A, Volikos E, Johnson V, Rogers P, Suraweera N, Tomlinson I, Phillips R, Silver A: APC mutations in FAP-associated desmoid tumours are non-random but not 'just right'. Hum Mol Genet 2007, 16:78-82.
- Miyaki M, Yamaguchi T, Iijima T, Takahashi K, Matsumoto H, Yasutome M, Funata N, Mori T: Difference in characteristics of APC mutations between colonic and extracolonic tumors of FAP patients: variations with phenotype. Int J Cancer 2008, 122:2491-2497.

- Matsumoto T, Lida M, Kobori Y, Mizuno M, Nakamura S, Hizawa K, Yao T: Genetic predisposition to clinical manifestations in familial adenomatous polyposis with special reference to duodenal lesions. *Am J Gastroenterol* 2002, 97:180-185.
- Andresen PA, Heimdal K, Aaberg K, Eklo K, Ariansen S, Silye A, Fausa O, Aabakken L, Aretz S, Eide TJ, Gedde-Dahl T Jr: APC mutation spectrum of Norwegian familial adenomatous polyposis families: high ratio of novel mutations. J Cancer Res Clin Oncol 2009, 135:1463-1470.
- Wachsmannova-Matelova L, Stevurkova V, Adamcikova Z, Holec V, Zajac V: Different phenotype manifestation of familial adenomatous polyposis in families with APC mutation at codon 1309. *Neoplasma* 2009, 56:486-489.
- Kanter-Smoler G, Fritzell K, Rohlin A, Engwall Y, Hallberg B, Bergman A, Meuller J, Grönberg H, Karlsson P, Björk J, Nordling M: Clinical characterization and the mutation spectrum in Swedish adenomatous polyposis families. *BMC Med* 2008, 6:10.
- Montera M, Piaggio F, Marchese C, Gismondi V, Stella A, Resta N, Varesco L, Guanti G, Mareni C: A silent mutation in exon 14 of the APC gene is associated with exon skipping in a FAP family. J Med Genet 2001, 38:863-867.
- Gonçalves V, Theisen P, Antunes O, Medeira A, Ramos JS, Jordan P, Isidro G: A missense mutation in the APC tumor suppressor gene disrupts an ASF/SF2 splicing enhancer motif and causes pathogenic skipping of exon 14. *Mutat Res* 2009, 662:33-36.

doi:10.1186/1756-0500-3-305

Cite this article as: Tao *et al.*: Identification of 5 novel germline *APC* mutations and characterization of clinical phenotypes in Japanese patients with classical and attenuated familial adenomatous polyposis. *BMC Research Notes* 2010 **3**:305.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

) BioMed Central

Submit your manuscript at www.biomedcentral.com/submit